Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

25 févr. 2019 09h11 HE | Source: ORPHAZYME A/S

Orphazyme Annual Report 2018 Presentation

Orphazyme A/SInvestor news No....
31 janv. 2019 02h53 HE | Source: ORPHAZYME A/S

Capital increase of 26,060 shares (equivalent to approximately 0.13% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KLSDC and UCLB

Orphazyme A/SCompany announcement No....
30 janv. 2019 13h48 HE | Source: ORPHAZYME A/S

Major shareholder announcement

Orphazyme A/SCompany announcement No....
30 janv. 2019 01h14 HE | Source: ORPHAZYME A/S

Orphazyme reports positive results from full data set of Phase II/III arimoclomol trial in Niemann-Pick disease Type C (NPC)

Orphazyme A/SCompany announcement No....
10 déc. 2018 04h38 HE | Source: ORPHAZYME A/S

Orphazyme expects to announce results of full data set for Niemann-Pick disease Type C (NPC) Phase II/III trial in Q1 2019

Orphazyme A/SCompany announcement No. 14/2018 Company Registration No....
27 nov. 2018 08h51 HE | Source: ORPHAZYME A/S

Publication of manuscript on preclinical Proof-of-Concept of arimoclomol in Gaucher disease

Orphazyme A/SInvestor news No....
20 nov. 2018 04h18 HE | Source: ORPHAZYME A/S

Orphazyme to present at Redeye Life Science Day

Orphazyme A/SInvestor news No....
08 nov. 2018 01h54 HE | Source: ORPHAZYME A/S

Financial calendar 2019

Orphazyme A/SCompany announcement No....
15 oct. 2018 03h08 HE | Source: ORPHAZYME A/S

Orphazyme endorses patient advocacy consensus guidelines, highlights importance of collaboration with patient communities

Orphazyme A/SInvestor News No....
28 sept. 2018 01h00 HE | Source: ORPHAZYME A/S

Orphazyme reports encouraging arimoclomol clinical trial top-line data in Niemann-Pick disease Type C (NPC)

Orphazyme A/SCompany announcement No....

Page précédente